Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort

Danja Sarink, Helena Schock, Theron Johnson, Kim Overvad, Marianne Holm, Anne Tjønneland, Marie Christine Boutron-Ruault, Mathilde His, Marina Kvaskoff, Heiner Boeing, Pagona Lagiou, Eleni Maria Papatesta, Antonia Trichopoulou, Domenico Palli, Valeria Pala, Amalia Mattiello, Rosario Tumino, Carlotta Sacerdote, H. B. Bueno-De-Mesquita, Carla H. Van GilsPetra H. Peeters, Elisabete Weiderpass, Antonio Agudo, Maria José Sánchez, Maria Dolores Chirlaque, Eva Ardanaz, Pilar Amiano, Kay Tee Khaw, Ruth Travis, Laure Dossus, Mark Gunter, Sabina Rinaldi, Melissa Merritt, Elio Riboli, Rudolf Kaaks, Renée T. Fortner

Research output: Contribution to journalArticle

Abstract

Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1, 976 incident invasive breast cancer cases [estrogen receptor positive (ER+), n=1, 598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet = 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01-1.63); Ptrend=0.20], but not ER-disease. For both ER+and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER-PR-disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14); Ptrend=0.03]. This study provides the first largescale prospective data on circulating sRANKLand breast cancer. We observed limited evidence for an association between sRANKLand breast cancer risk. Cancer Prev Res; 10(9); 525-34.

Original languageEnglish
Pages (from-to)525-534
Number of pages10
JournalCancer Prevention Research
Volume10
Issue number9
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

RANK Ligand
Osteoprotegerin
Breast Neoplasms
Neoplasms
Receptor Activator of Nuclear Factor-kappa B
Odds Ratio
Estrogen Receptors
Hormones
kappa Opioid Receptor
Progesterone Receptors
Serum
Case-Control Studies
Theoretical Models
Logistic Models
Enzyme-Linked Immunosorbent Assay
Confidence Intervals

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sarink, D., Schock, H., Johnson, T., Overvad, K., Holm, M., Tjønneland, A., ... Fortner, R. T. (2017). Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort. Cancer Prevention Research, 10(9), 525-534. https://doi.org/10.1158/1940-6207.CAPR-17-0125

Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype : Results from the EPIC cohort. / Sarink, Danja; Schock, Helena; Johnson, Theron; Overvad, Kim; Holm, Marianne; Tjønneland, Anne; Boutron-Ruault, Marie Christine; His, Mathilde; Kvaskoff, Marina; Boeing, Heiner; Lagiou, Pagona; Papatesta, Eleni Maria; Trichopoulou, Antonia; Palli, Domenico; Pala, Valeria; Mattiello, Amalia; Tumino, Rosario; Sacerdote, Carlotta; Bueno-De-Mesquita, H. B.; Van Gils, Carla H.; Peeters, Petra H.; Weiderpass, Elisabete; Agudo, Antonio; Sánchez, Maria José; Chirlaque, Maria Dolores; Ardanaz, Eva; Amiano, Pilar; Khaw, Kay Tee; Travis, Ruth; Dossus, Laure; Gunter, Mark; Rinaldi, Sabina; Merritt, Melissa; Riboli, Elio; Kaaks, Rudolf; Fortner, Renée T.

In: Cancer Prevention Research, Vol. 10, No. 9, 01.09.2017, p. 525-534.

Research output: Contribution to journalArticle

Sarink, D, Schock, H, Johnson, T, Overvad, K, Holm, M, Tjønneland, A, Boutron-Ruault, MC, His, M, Kvaskoff, M, Boeing, H, Lagiou, P, Papatesta, EM, Trichopoulou, A, Palli, D, Pala, V, Mattiello, A, Tumino, R, Sacerdote, C, Bueno-De-Mesquita, HB, Van Gils, CH, Peeters, PH, Weiderpass, E, Agudo, A, Sánchez, MJ, Chirlaque, MD, Ardanaz, E, Amiano, P, Khaw, KT, Travis, R, Dossus, L, Gunter, M, Rinaldi, S, Merritt, M, Riboli, E, Kaaks, R & Fortner, RT 2017, 'Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort', Cancer Prevention Research, vol. 10, no. 9, pp. 525-534. https://doi.org/10.1158/1940-6207.CAPR-17-0125
Sarink, Danja ; Schock, Helena ; Johnson, Theron ; Overvad, Kim ; Holm, Marianne ; Tjønneland, Anne ; Boutron-Ruault, Marie Christine ; His, Mathilde ; Kvaskoff, Marina ; Boeing, Heiner ; Lagiou, Pagona ; Papatesta, Eleni Maria ; Trichopoulou, Antonia ; Palli, Domenico ; Pala, Valeria ; Mattiello, Amalia ; Tumino, Rosario ; Sacerdote, Carlotta ; Bueno-De-Mesquita, H. B. ; Van Gils, Carla H. ; Peeters, Petra H. ; Weiderpass, Elisabete ; Agudo, Antonio ; Sánchez, Maria José ; Chirlaque, Maria Dolores ; Ardanaz, Eva ; Amiano, Pilar ; Khaw, Kay Tee ; Travis, Ruth ; Dossus, Laure ; Gunter, Mark ; Rinaldi, Sabina ; Merritt, Melissa ; Riboli, Elio ; Kaaks, Rudolf ; Fortner, Renée T. / Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype : Results from the EPIC cohort. In: Cancer Prevention Research. 2017 ; Vol. 10, No. 9. pp. 525-534.
@article{46e39539084847d9b02cfc05a1e66409,
title = "Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort",
abstract = "Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1, 976 incident invasive breast cancer cases [estrogen receptor positive (ER+), n=1, 598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and95{\%} confidence intervals (95{\%} CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet = 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95{\%} CI, 1.01-1.63); Ptrend=0.20], but not ER-disease. For both ER+and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER-PR-disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14); Ptrend=0.03]. This study provides the first largescale prospective data on circulating sRANKLand breast cancer. We observed limited evidence for an association between sRANKLand breast cancer risk. Cancer Prev Res; 10(9); 525-34.",
author = "Danja Sarink and Helena Schock and Theron Johnson and Kim Overvad and Marianne Holm and Anne Tj{\o}nneland and Boutron-Ruault, {Marie Christine} and Mathilde His and Marina Kvaskoff and Heiner Boeing and Pagona Lagiou and Papatesta, {Eleni Maria} and Antonia Trichopoulou and Domenico Palli and Valeria Pala and Amalia Mattiello and Rosario Tumino and Carlotta Sacerdote and Bueno-De-Mesquita, {H. B.} and {Van Gils}, {Carla H.} and Peeters, {Petra H.} and Elisabete Weiderpass and Antonio Agudo and S{\'a}nchez, {Maria Jos{\'e}} and Chirlaque, {Maria Dolores} and Eva Ardanaz and Pilar Amiano and Khaw, {Kay Tee} and Ruth Travis and Laure Dossus and Mark Gunter and Sabina Rinaldi and Melissa Merritt and Elio Riboli and Rudolf Kaaks and Fortner, {Ren{\'e}e T.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1158/1940-6207.CAPR-17-0125",
language = "English",
volume = "10",
pages = "525--534",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype

T2 - Results from the EPIC cohort

AU - Sarink, Danja

AU - Schock, Helena

AU - Johnson, Theron

AU - Overvad, Kim

AU - Holm, Marianne

AU - Tjønneland, Anne

AU - Boutron-Ruault, Marie Christine

AU - His, Mathilde

AU - Kvaskoff, Marina

AU - Boeing, Heiner

AU - Lagiou, Pagona

AU - Papatesta, Eleni Maria

AU - Trichopoulou, Antonia

AU - Palli, Domenico

AU - Pala, Valeria

AU - Mattiello, Amalia

AU - Tumino, Rosario

AU - Sacerdote, Carlotta

AU - Bueno-De-Mesquita, H. B.

AU - Van Gils, Carla H.

AU - Peeters, Petra H.

AU - Weiderpass, Elisabete

AU - Agudo, Antonio

AU - Sánchez, Maria José

AU - Chirlaque, Maria Dolores

AU - Ardanaz, Eva

AU - Amiano, Pilar

AU - Khaw, Kay Tee

AU - Travis, Ruth

AU - Dossus, Laure

AU - Gunter, Mark

AU - Rinaldi, Sabina

AU - Merritt, Melissa

AU - Riboli, Elio

AU - Kaaks, Rudolf

AU - Fortner, Renée T.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1, 976 incident invasive breast cancer cases [estrogen receptor positive (ER+), n=1, 598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet = 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01-1.63); Ptrend=0.20], but not ER-disease. For both ER+and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER-PR-disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14); Ptrend=0.03]. This study provides the first largescale prospective data on circulating sRANKLand breast cancer. We observed limited evidence for an association between sRANKLand breast cancer risk. Cancer Prev Res; 10(9); 525-34.

AB - Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1, 976 incident invasive breast cancer cases [estrogen receptor positive (ER+), n=1, 598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet = 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01-1.63); Ptrend=0.20], but not ER-disease. For both ER+and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER-PR-disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14); Ptrend=0.03]. This study provides the first largescale prospective data on circulating sRANKLand breast cancer. We observed limited evidence for an association between sRANKLand breast cancer risk. Cancer Prev Res; 10(9); 525-34.

UR - http://www.scopus.com/inward/record.url?scp=85029542301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029542301&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-17-0125

DO - 10.1158/1940-6207.CAPR-17-0125

M3 - Article

AN - SCOPUS:85029542301

VL - 10

SP - 525

EP - 534

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 9

ER -